Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

1. Community-wide Screening for Tuberculosis in a High-Prevalence Setting. (PubMed)

Community-wide Screening for Tuberculosis in a High-Prevalence Setting. The World Health Organization has set ambitious targets for the global elimination of tuberculosis. However, these targets will not be achieved at the current rate of progress.We performed a cluster-randomized, controlled trial in Ca Mau Province, Vietnam, to evaluate the effectiveness of active community-wide screening, as compared with standard passive case detection alone, for reducing the prevalence of tuberculosis (...) . Persons 15 years of age or older who resided in 60 intervention clusters (subcommunes) were screened for pulmonary tuberculosis, regardless of symptoms, annually for 3 years, beginning in 2014, by means of rapid nucleic acid amplification testing of spontaneously expectorated sputum samples. Active screening was not performed in the 60 control clusters in the first 3 years. The primary outcome, measured in the fourth year, was the prevalence of microbiologically confirmed pulmonary tuberculosis among

2019 NEJM

2. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. (PubMed)

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk.Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon).A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection (...) of outcome measures.Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%).Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence.Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach.Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk

2019 BMJ

3. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. (PubMed)

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. Recent 15-year updates of sigmoidoscopy screening trials provide new evidence on the effectiveness of colorectal cancer screening. Prompted by the new evidence, we asked: "Does colorectal cancer screening make an important difference to health outcomes in individuals initiating screening at age 50 to 79? And which screening option is best?"Numerous guidelines recommend (...) screening, but vary on recommended test, age and screening frequency. This guideline looks at the evidence and makes recommendations on screening for four screening options: faecal immunochemical test (FIT) every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy.These recommendations apply to adults aged 50-79 years with no prior screening, no symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 15-year colorectal cancer

2019 BMJ

4. Breast screening: higher risk women surveillance protocols

Breast screening: higher risk women surveillance protocols Breast screening: higher risk women surveillance protocols - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Breast screening: higher risk women surveillance protocols The NHS breast surveillance protocols for women at higher risk of developing breast cancer. Published 1 June 2013 Last updated 8 July 2019 — From: Documents If you use assistive (...) technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. format This file may not be suitable for users of assistive technology. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive

2019 Public Health England

5. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) for breast cancer diagnosis? What is the comparative clinical effectiveness of synthetic 2D mammography compared with conventional 2D digital mammography obtained with 3D digital tomosynthesis? What is the cost effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer screening or diagnosis? What are the evidence-based guidelines regarding the use of 3D digital tomosynthesis for breast cancer screening and diagnosis? Key Message Seven

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines

Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines Urinary Dipstick Testing for Bladder Cancer Screening: Diagnostic Accuracy, Clinical Effectiveness and Guidelines (...) Last updated: April 1, 2019 Project Number: RB1320-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the diagnostic accuracy of urinary dipstick testing for bladder cancer screening in asymptomatic adult patients with microscopic hematuria? What is the clinical effectiveness of urinary dipstick testing for bladder cancer screening in asymptomatic adult patients? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Screening for Vancomycin-Resistant Enterococci in Patients Admitted to Hospital: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Screening for Vancomycin-Resistant Enterococci in Patients Admitted to Hospital: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Screening for Vancomycin-Resistant Enterococci in Patients Admitted to Hospital: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Screening for Vancomycin-Resistant Enterococci in Patients Admitted to Hospital: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Screening for Vancomycin-Resistant (...) Enterococci in Patients Admitted to Hospital: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: July 17, 2019 Project Number: RB1362-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of selective screening versus universal screening or no screening of vancomycin-resistant enterococci in patients admitted to hospital? What is the cost-effectiveness of selective screening versus

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines

Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Last updated: June 24, 2019 Project Number: RA1043-000 Product Line: Research Type: Devices and Systems Report Type (...) : Reference List Result type: Report Question What is the clinical effectiveness of interventions used to screen individuals for tuberculosis? What are the evidence-based guidelines regarding the screening of individuals for tuberculosis? Key Message Twelve systematic reviews (eight with meta-analysis) were identified regarding the clinical effectivenessof interventions used to screen individuals for tuberculosis. In addition, four evidence-based guidelines were identified regarding the screening

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines

Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines | CADTH.ca Find the information you need Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines Last updated: August 13 (...) , 2019 Project Number: RA1058-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical utility of screening triage tools and/or management algorithms in adult patients in the emergency department with suspected sepsis? What is the clinical utility of screening triage tools and/or management algorithms in adult inpatients with suspected sepsis? What are the evidence-based guidelines regarding the use of screening triage tools

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update

HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update | CADTH.ca Find the information you need HPV Self-Sampling for Primary Cervical Cancer Screening: A Review of Diagnostic Test Accuracy and Clinical Evidence – An Update HPV Self-Sampling for Primary Cervical Cancer Screening: A Review (...) of Diagnostic Test Accuracy and Clinical Evidence – An Update Last updated: May 30, 2019 Project Number: RC1124-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the diagnostic test accuracy of self-sampled HPV tests compared with clinician-sampled HPV tests or cytology for asymptomatic cervical cancer screening? What is the clinical evidence regarding the agreement or concordance of self-sampled HPV tests and clinician

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Anal Cancer Screening in High Risk Populations: Clinical Effectiveness (...) , Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: September 20, 2019 Project Number: RB1400-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of anal cancer screening in high risk populations? What is the diagnostic accuracy of Pap testing for anal cancer in high risk populations? What is the cost-effectiveness of anal cancer screening in high risk populations? What are the evidence-based

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Breast screening: breast implant guidelines

Breast screening: breast implant guidelines Breast screening: breast implant guidelines - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Promotional material Breast screening: breast implant guidelines This leaflet (...) provides information about NHS breast screening for women with breast implants. Published 1 June 2010 Last updated 1 October 2019 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. HTML Details Healthcare professionals can use this information to tell women about how breast implants affect screening

2019 Public Health England

13. Asymptomatic Bacteriuria in Adults: Screening

Asymptomatic Bacteriuria in Adults: Screening Final Recommendation Statement: Asymptomatic Bacteriuria in Adults: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Asymptomatic Bacteriuria in Adults: Screening Recommendations made by the USPSTF are independent of the U.S. government. They should (...) not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Pregnant persons The USPSTF recommends screening for asymptomatic bacteriuria using urine culture in pregnant persons. Nonpregnant adults The USPSTF recommends against screening for asymptomatic bacteriuria in nonpregnant adults. To read the recommendation statement in JAMA , select . To read the evidence summary

2019 U.S. Preventive Services Task Force

14. Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02

Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02 1 Translation of the executive summary of the addendum S16-01 Screening auf asymptomatische Bakteriurie im Rahmen der Mutterschafts-Richtlinien unter besonderer Berücksichtigung der Testmethoden – Addendum zum Auftrag S13-02 (Version 1.0; Status: 19 October 2016). Please note: This document was translated by an external (...) translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-01 Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods – Addendum to Commission S13-02 1 Extract of addendum S16-01 Version 1.0 Screening for bacteriuria in pregnant women 19 October 2016 Institute for Quality

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

15. Screening for depression

Screening for depression 1 Translation of the key statement of the final report S16-05 Screening auf Depression (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-05 Screening for depression 1 Extract of final report S16-05 Version 1.0 Screening (...) for depression 27 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for depression Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2016 Internal Commission No.: S16-05 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

16. Screening for hepatitis C

Screening for hepatitis C 1 Translation of the key statement of the final report S16-04 Screening auf Hepatitis C (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-04 Screening for hepatitis C 1 Extract of final report S16-04 Version 1.0 (...) Screening for hepatitis C 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis C Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-04 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

17. Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines

Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Last updated: January 14, 2019 Project Number: RB1297-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of dietary/nutrition priority screening tools for in-patients and outpatients with chronic kidney disease? What are the evidence-based guidelines for the use of dietary/nutrition prioritization tools for the delivery of nutritional therapy in the chronic kidney disease setting? Key Message One non-randomized study and three evidence based guidelines were identified regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. HPV Testing for Primary Cervical Cancer Screening

HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening | CADTH.ca Find the information you need HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening Published on: March 26, 2019 Project Number: OP0530-000 Product Line: Result type: Report Worldwide, cervical cancer is one of the most frequently diagnosed cancers; however, the incidence of cervical cancer has been decreasing in the past three decades (...) , largely due to routine screening with cytology. HPV is the major risk factor for the development of cervical cancer, with 99% of cervical cancer being associated with HPV. It is one of the most common sexually transmitted infections in the world and about three out of every four sexually active Canadians will have at least one HPV infection at some point in their lives. In view of the anticipated higher sensitivity of HPV testing, some experts and stakeholders have called for HPV testing to be used

2019 CADTH - Optimal Use

19. Colorectal Cancer Screening Evidence Brief

Colorectal Cancer Screening Evidence Brief 1 Age to Initiate Colorectal Cancer Screening in Average Risk Individuals: Evidence Brief, June 2019 Key Points • Colorectal cancer incidence and mortality are increasing in individuals under age 50. • Simulation models suggest there may be benefit to screening average risk patients beginning at age 45, but it is unclear if this benefit outweighs the risks of screening • Patients age 45-49 who express interest in screening should be engaged in shared (...) -decision making to discuss the risks and benefits • It is strongly recommended that all average risk patients 50 years and older should be screened for colon cancer • Extra vigilance for symptoms and risk factors of colon cancer (including family history in people aged 45-49) is advised given increasing colorectal cancer rates in this group. Definition of Average Risk This guidance applies to individuals at average risk for colorectal cancer. Patients not considered average risk include those

2019 Institute for Clinical Systems Improvement

20. Screening and Management of the Hyperandrogenic Adolescent

Screening and Management of the Hyperandrogenic Adolescent ACOGCOMMITTEEOPINION Number 789 Committee on Adolescent Health Care This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care in collaboration with committee members Jennie Yoost, MD and Ashlyn Savage, MD. Screening and Management of the Hyperandrogenic Adolescent ABSTRACT: Although androgen excess can manifest in many ways, the most common and recognizable (...) of PCOS and those of normal puberty,whichmakesthediagnosisofPCOSintheadolescentdifficult.Treatmentofacneandhirsutismshould not be withheld during the ongoing longitudinal evaluation for possible PCOS. On physical examination, body mass index, blood pressure, and signs of hyperandrogenism, such as acne and hirsutism, should be evaluated. Although guidelines differ on recommended laboratory studies, most include measurement of total testoster- one, free testosterone, or both, and screening

2019 American College of Obstetricians and Gynecologists